NEW YORK (GenomeWeb News) – CombiMatrix has signed an agreement with an institutional investor for a registered direct offering that is expected to provide the firm with $2 million in gross proceeds, or $1.76 million in net proceeds.

The firm said that it has entered into a definitive purchase agreement with the unnamed investor to purchase 130,000 shares of common stock for $3.05 per share and approximately 1,610 units consisting of Series B convertible preferred stock and warrants. Shares of CombiMatrix closed Tuesday at $3.20 on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.